The complexities of the pathology-pathogenesis relationship in Alzheimer disease.
暂无分享,去创建一个
[1] C. Haass,et al. Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.
[2] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[3] Mark E. Schmidt,et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[4] P. S. St George-Hyslop,et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. , 1987, Science.
[5] Bengt Winblad,et al. Defective brain microtubule assembly in Alzheimer??s disease , 1987 .
[6] Brian J Bacskai,et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] D. Selkoe,et al. Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. , 1999, The Biochemical journal.
[8] P. Schofield,et al. Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions. , 2003, Brain : a journal of neurology.
[9] S ORAM,et al. STAPHYLOCOCCI RESISTANT TO NEOMYCIN AND BACITRACIN. , 1965, Lancet.
[10] Colin L Masters,et al. Crystal Structure of the Amyloid-β p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease , 2011, The Journal of Neuroscience.
[11] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[12] K. Grzeschik,et al. The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor , 1987 .
[13] M. Kidd. Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease , 1963, Nature.
[14] J. Morrison,et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.
[15] M. Graeber,et al. Reanalysis of the first case of Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[16] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[17] C. Brayne,et al. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. , 2009, Journal of Alzheimer's disease : JAD.
[18] M. Mendez,et al. Frontotemporal Dementia-like Phenotypes Associated With Presenilin-1 Mutations , 2006, American journal of Alzheimer's disease and other dementias.
[19] R. Castellani,et al. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. , 2012, Archives of medical research.
[20] J. Price,et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.
[21] M. Roth,et al. The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.
[22] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[23] Bradley T. Hyman,et al. Tau pathophysiology in neurodegeneration: a tangled issue , 2009, Trends in Neurosciences.
[24] M. Wolfe. Tau Mutations in Neurodegenerative Diseases* , 2009, Journal of Biological Chemistry.
[25] K. Jellinger,et al. Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.
[26] W. Pardridge,et al. Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. , 2000, Bioconjugate chemistry.
[27] Z. Khachaturian. Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.
[28] K. Blennow,et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[29] H. Möller,et al. The case described by Alois Alzheimer in 1911 , 1998, European Archives of Psychiatry and Clinical Neuroscience.
[30] M. Doran,et al. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.
[31] R. Castellani,et al. Molecular Pathology of Alzheimer's Disease , 2013 .
[32] S. Younkin. Evidence that Aβ42 is the real culprit in alzheimer's disease , 1995 .
[33] Shankar Vallabhajosula,et al. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. , 2011, Seminars in nuclear medicine.
[34] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[35] F. Tarazi,et al. Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive? , 2013, Expert opinion on biological therapy.
[36] P. S. St George-Hyslop,et al. Familial Dementia With Frontotemporal Features Associated With M146V Presenilin‐1 Mutation , 2013, Brain pathology.
[37] R. Castellani,et al. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’ , 2011, The Journal of pathology.
[38] M. Graeber,et al. A presenilin 1 mutation in the first case of Alzheimer's disease , 2013, The Lancet Neurology.
[39] Charles Duyckaerts,et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.
[40] S. Younkin. Evidence that A beta 42 is the real culprit in Alzheimer's disease. , 1995, Annals of neurology.
[41] Peter R Schofield,et al. The Genetics of Dementia , 2013 .
[42] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[43] C. Masters,et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[44] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[45] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[46] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[47] H. Braak,et al. Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship , 2009, Journal of neuropathology and experimental neurology.